Geschatte realtime
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
4,57 USD | +1,33% | -6,69% | -26,63% |
13/03 | Transcript : ScPharmaceuticals Inc., Q4 2023 Earnings Call, Mar 13, 2024 | |
13/03 | ScPharmaceuticals Inc. rapporteert resultaten voor het vierde kwartaal dat eindigde op 31 december 2023 | CI |
Omzet 2024 * | 40,03 mln. 37,53 mln. | Omzet 2025 * | 97,75 mln. 91,64 mln. | Marktkapitalisatie | 163 mln. 152 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -58 mln. -54,38 mln. | Nettowinst (verlies) 2025 * | -26 mln. -24,38 mln. | EV/omzet 2024 * | 4,06 x |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 1,66 x |
K/w-verhouding 2024 * |
-3,05
x | K/w-verhouding 2025 * |
-7,31
x | Werknemers | 136 |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 86,93% |
Recentste transcriptie over scPharmaceuticals Inc.
1 dag | +1,22% | ||
1 week | -6,69% | ||
Lopende maand | -8,37% | ||
1 maand | -14,34% | ||
3 maanden | -13,86% | ||
6 maanden | -21,37% | ||
Lopend jaar | -26,63% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
John Tucker
CEO | Chief Executive Officer | 61 | 01-01-17 |
Rachael Nokes
DFI | Director of Finance/CFO | 49 | 01-09-14 |
John Mohr
CTO | Chief Tech/Sci/R&D Officer | - | 01-02-17 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Director/Board Member | 78 | 01-01-14 | |
Klaus Veitinger
BRD | Director/Board Member | 62 | 21-11-17 |
John Tucker
CEO | Chief Executive Officer | 61 | 01-01-17 |
Naam | Gewicht | Volume | Vaira. 1 jan. | belegger rating |
---|---|---|---|---|
0.00% | 34 M€ | +1,44% | - |
Datum | Koers | Variatie | Volume |
---|---|---|---|
19-04-24 | 4,6 | +2,00% | 41 644 |
18-04-24 | 4,51 | +2,04% | 223 905 |
17-04-24 | 4,42 | -5,35% | 249 573 |
16-04-24 | 4,67 | -3,91% | 126 229 |
15-04-24 | 4,86 | -1,42% | 184 123 |
uitgestelde koers Nasdaq, 19 april 2024 om 17:25 uur
Meer koersenHerzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
-26,63% | 163 mln. | |
+25,51% | 672 mld. | |
+24,08% | 550 mld. | |
-6,54% | 351 mld. | |
+14,81% | 317 mld. | |
+6,79% | 292 mld. | |
+3,19% | 211 mld. | |
+0,53% | 203 mld. | |
-10,49% | 144 mld. | |
-7,95% | 141 mld. |